Sep 9, 2024 7:30 am EDT FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Aug 5, 2024 7:30 am EDT Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Jun 27, 2024 8:00 am EDT Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Jun 24, 2024 8:00 am EDT Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
Jun 13, 2024 11:30 pm EDT Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
Jun 13, 2024 4:01 pm EDT Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 21, 2024 4:05 pm EDT Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
